Pharmacology of Aminophylline for Acute Kidney Injury in Neonates

Not Recruiting

Trial ID: NCT02276170

Age - N/A-3 Months Condition - Neonatal and Developmental Medicine Gender - All Accepting Healthy Volunteers - No

Purpose

Acute kidney injury (AKI) in critically ill neonates is common and associated with significant morbidity and mortality. No targeted therapeutic treatment strategies have been established for AKI in neonates. Within a clinical pharmacokinetic and pharmacodynamic conceptual framework, this project will examine the medication aminophylline as a potential treatment approach for AKI.

Eligibility


Inclusion Criteria:

   - Neonate < 3 months post natal age

   - Diagnosed with acute kidney injury (AKI)

   - Receiving aminophylline for AKI treatment as per local standard of care.

Exclusion Criteria:

   - Presence of anatomical renal anomaly based on postnatal evaluation of the patient
   (hydronephrosis, multicystic kidney, renal agenesis, renal dysplasia, polycystic
   kidney, or obstructive uropathy)

   - Patient on renal replacement therapy

   - Major genetic abnormalities (trisomy 13, 18 or 21).

View More
View Less

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305

©2024 Stanford Medicine